Editorial
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jul 25, 2015; 6(8): 990-998
Published online Jul 25, 2015. doi: 10.4239/wjd.v6.i8.990
Metabolic surgery: A paradigm shift in type 2 diabetes management
Joseph M Pappachan, Ananth K Viswanath
Joseph M Pappachan, Ananth K Viswanath, Department of Endocrinology and Diabetes, New Cross Hospital, the Royal Wolverhampton Hospital NHS Trust, Wolverhampton WV10 0QP, United Kingdom
Author contributions: Viswanath AK conceived the idea; Pappachan JM wrote the initial draft of the paper; both authors contributed to literature search and final preparation of the manuscript.
Conflict-of-interest statement: Ananth K Viswanath received lecture fees from MSD, NovoNordisk, Takeda, Eilly Lilly, Jansen and sponsorship from NovoNordisk, Takeda, Novartis and Jansen to attend international conferences. Joseph M Pappachan has no conflicts of interest to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Joseph M Pappachan, MD, MRCP (London), Department of Endocrinology and Diabetes, New Cross Hospital, the Royal Wolverhampton Hospital NHS Trust, Wolverhampton Road, Wolverhampton WV10 0QP, United Kingdom. drpappachan@yahoo.co.in
Telephone: +44-1922-721172 Fax: +44-1922-721172
Received: April 12, 2015
Peer-review started: April 15, 2015
First decision: April 27, 2015
Revised: April 30, 2015
Accepted: May 27, 2015
Article in press: May 28, 2015
Published online: July 25, 2015

Abstract

Obesity and type 2 diabetes mellitus (T2DM) are major public health issues globally over the past few decades. Despite dietary interventions, lifestyle modifications and the availability of several pharmaceutical agents, management of T2DM with obesity is a major challenge to clinicians. Metabolic surgery is emerging as a promising treatment option for the management of T2DM in the obese population in recent years. Several observational studies and a few randomised controlled trials have shown clear benefits of various bariatric procedures in obese individuals in terms of improvement or remission of T2DM and multiple other health benefits such as improvement of hypertension, obstructive sleep apnoea, osteoarthritis and non-alcoholic fatty liver disease. Uncertainties about the long-term implications of metabolic surgery such as relapse of T2DM after initial remission, nutritional and psychosocial complications and the optimal body mass index for different ethnic groups exist. The article discusses the major paradigm shift in recent years in the management of T2DM after the introduction of metabolic surgery.

Key Words: Metabolic surgery, Bariatric procedures, Type 2 diabetes mellitus, Body mass index, Diabetes remission

Core tip: Metabolic surgery or bariatric surgery has revolutionised the 21st century management of type 2 diabetes mellitus (T2DM) in obese patients. Marked reduction of body weight following the bariatric procedures results in improvement or remission of T2DM in a significant number of patients along with improvement of other diseases associated with obesity such as hypertension, obstructive sleep apnoea, osteoarthritis and non-alcoholic fatty liver disease. Uncertainty exists about the long-term outcomes in terms of diabetes relapse, nutritional and psychosocial complications. However, the marked benefits of metabolic surgery outweigh the risks related to the procedure that has resulted in a major paradigm shift in the management of obese population with T2DM in recent years which is the topic of discussion of this paper.



METABOLIC SURGERY: A PARADIGM SHIFT IN TYPE 2 DIABETES MANAGEMENT

Obesity has become a global pandemic in recent years that affects more than 600 million adults worldwide[1]. World Health Organization estimated that 39% of adults aged 18 years and over were overweight [body mass index (BMI) ≥ 25 kg/m2; more than 1.8 billion persons], and 13% were obese (BMI ≥ 30 kg/m2) in the year 2014. A majority of these individuals reside in the developed countries although obesity and overweight are major public health issues even in developing nations. The National Health and Nutrition Examination Survey 2011-2012 regarding population prevalence in obesity revealed that 34.9% of the adults were obese and 33.6% were overweight in the United States[2]. Although data on the prevalence of obesity is scant from most other countries, comparable figures probably exist in many developed countries.

Obesity is a major risk factor for type 2 diabetes mellitus (T2DM). By 2014 diabetes affected 387 million people worldwide and 4.9 million deaths in 2014 alone were directly related to diabetes[3]. The global diabetes disease burden is mainly from T2DM and a majority of these cases are related to obesity. Despite diet and lifestyle interventions and the availability of pharmaceutical agents with weight losing properties the long-term management of obesity with these measures are disappointing. Different gastric bypass procedures collectively termed as bariatric surgery/metabolic surgery have emerged as very promising methods to treat obesity in the past 3 decades that can improve and potentially cure diabetes and many other diseases related to obesity. Through this paper we discuss the major paradigm shift in the management of T2DM in recent years after the introduction of metabolic surgery. We also discuss the long-term health benefits, adverse complications and emerging research questions related to metabolic surgery.

TYPES AND EFFICACY OF DIFFERENT BARIATRIC PROCEDURES

Although there are a multitude of bariatric procedures developed over the past 50 years the common techniques used in present day clinical practice are adjustable gastric banding (AGB), sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB) and bilio-pancreatic diversion (BPD). The different surgical procedures are depicted in the Figure 1.

Figure 1
Figure 1 The diagrammatic representation of different bariatric surgical procedures. A: Adjustable gastric band; B: Sleeve gastrectomy; C: Roux-en-Y gastric bypass; D: Bilio-pancreatic diversion. Figure reproduced with permission from John Wiley and Sons. Obesity (Silver Spring) 2013 Mar; 21 Suppl 1: S1-27.

AGB and SG are predominantly restrictive procedures whereas RYGB and BPD are mainly mal-absorptive procedures that reduce effective area of nutrient absorption in the intestinal mucosa. Food passes through the alimentary limb in RYGB and BPD with gastrointestinal secretions in the bilio-pancreatic limb mixing with the nutrients where both limbs form the common channel.

In various randomised controlled trials (RCTs), the reported mean percentage (%) excess body weight loss (with 95%CI in parenthesis) achieved at one year after AGB, SG and RYGB were 33.39 (22.57-44.21), 69.70 (41.09-98.32) and 72.32 (64.60-80.04) respectively[4]. The % excess weight loss (%EWL) reported with BPD was 76.89 ± 1.53 that is significantly higher than RYGB (67.17 ± 1.43; P = 0.0004)[5]. AGB procedures are losing popularity in the recent years because of inferior efficacy and the necessity for repeated surgery in a higher proportion of cases years after the initial surgery[6]. Although BPD is associated with a significantly higher %EWL and T2DM remission compared to other bariatric procedures the post-operative complication rates are higher[7] making this a less preferred operation.

BARIATRIC SURGERY IN T2DM

The major RCTs reporting the effects of metabolic surgery on T2DM are summarised in Table 1. The total number of patients in these RCTs is relatively small for a common condition like T2DM and the duration of follow-up is limited to 12-24 mo. However there are cohort studies and non-randomized trials reporting benefits of metabolic surgery from different regions of the world. There are also a few systematic reviews and meta-analyses reporting the beneficial effects of bariatric procedures in T2DM.

Table 1 Major randomised controlled trials reporting effects of metabolic surgical procedure on type 2 diabetes mellitus.
RCTStudy detailsOutcomeDiabetes remission
Dixon et al[8]Un-blinded RCT. N = 60 Obese patients with recent onset T2DM Conventional therapy vs LAGB Follow-up: 2 yrWeight loss –1.7% ± 5.2% in conventional group and –20.7% ± 8.6% in the surgical group73% in surgical group 13% in conventional group (Remission of T2DM defined as FBS < 7.0 mmol/L and HbA1c < 6.2%)
Mingrone et al[7]Single centre non-blinded RCT. N = 60. Severely obese patients. T2DM of at least 5 yr duration and HbA1c > 7.0%. Conventional medical therapy vs RYGB or BPD Follow-up: 2 yrWeight loss −4.7% ± 6.3% with medical therapy, −33.3% ± 7.8% with RYGB and −33.8% ± 10.1% with BPD75% in RYGB group; 95% in BPD group. None in the conventional group (Remission defined as FBS < 5.6 mmol/L and HbA1c < 6.5%)
Schauer et al[9]Single centre non-blinded RCT in obese uncontrolled T2DM. N = 150 Intensive medical therapy vs RYGB or SG Follow-up: 12 moWeight loss –5.4 ± 8.0 kg in medical therapy group, -29.4 ± 9.0 kg in RYGB group and –25.1 ± 8.5 kg in SG group12% medical therapy group 42% in RYGB group 37% SG group (Remission/primary outcome defined as HbA1c of 6% or less)
Ikramuddin et al[10]Un-blinded RCT in obese T2DM with HbA1c over 8% with average duration of 9 yr. N = 120 Intensive medical therapy vs RYGB Follow-up: 12 moDifference in weight loss between surgical and medical group –17.1 ± 5.6 kg. % weight change in medical vs Surgical group –7.9 ± 2 vs–26 ± 275% RYGB group 32% in medical group (Remission defined as HbA1c < 7%)
Liang et al[11]RCT in obese T2DM. N = 108. RYGB compared with standard care with or without Exenatide therapy Follow-up: 12 moReduction in BMI (kg/m2) in standard vs Exenatide vs RYGB: –0.56 ± 1.66 vs–3.44 ± 1.21 vs–5.97 ± 0.9190% in RYGB group None in patients receiving standard care with or without Exenatide (Remission defined as HbA1c < 6.5%)

In a meta-analysis of weight loss and remission of T2DM evaluated in RCTs and observational studies (OBS) of bariatric surgery vs conventional medical therapy over a 17 mo period the mean excess weight loss (EWL) for the bariatric surgery and the conventional treatment groups were 75.3% and 11.3% respectively; the corresponding T2DM remission rates were 63.5% and 15.6%[12]. The limitation of the meta-analysis was that many short-term OBS were included and surgery was not always compared directly to more vigorous medical weight loss interventions. There was lack of standardization in the definition of diabetes remission and it was unclear how specific bariatric procedures were chosen or what criteria were used for performing bariatric surgery.

A comparison of the mean changes in BMI and haemoglobin A1c (HbA1c) achieved with individual procedures[12] are shown in the Table 2.

Table 2 The mean changes in body mass index and haemoglobin A1c achieved with different gastric bypass procedures.
BariatricBody mass index (kg/m2)
HbA1c (%)
procedurePre-surgeryPost-surgeryMean reduction (95%CI)Pre-surgeryPost-surgeryMean reduction (95%CI)
AGB3729.57.5 (5.9-9.1)7.861.8 (1.3-2.3)
SG41.328.313.0 (10.1-15.9)7.961.9 (1.0-2.8)
RYGB34.625.88.8 (5.2-12.4)8.26.12.1 (1.3-2.9)
BPD50.534.615.9 (11.8-20.0)85.22.8 (2.1-3.5)

A few long-term cohort studies give us insight on the beneficial effects of metabolic surgery in T2DM[16]. For example, the Swedish Obese Subjects (SOS) study, started in 1987 is a prospective case-control study with 2010 obese subjects who underwent bariatric procedures (predominantly vertical banded gastrostomy which is considered to be less effective and no longer undertaken)[16,17]. A 72% remission of T2DM after two years and 36% durable remission after 10 years were observed in obese subjects in the SOS study[16,18]. Compared to control the risk of developing T2DM was reduced by 96%, 84%, and 78% after 2, 10, and 15 years in obese subjects without T2DM at baseline[19].

Utah obesity study retrospectively compared 7925 obese subjects who underwent RYGB with the same number of age, sex and weight matched controls and after an average follow up period of 7.1 years, found a 40% reduction in all cause mortality, 49% reduction of mortality from cardiovascular diseases and 92% reduction of death related to T2DM[20]. The Longitudinal Assessment of Bariatric Surgery (LABS-2) study is an ongoing multi-center cohort study that showed T2DM remission in 67% and 28% of those who underwent RYGB and AGB respectively after 3 years of follow up[21].

MECHANISMS OF DIABETES IMPROVEMENT/REMISSION FOLLOWING METABOLIC SURGERY
Reduction in calorie intake

Typically, patients are put on a calorie-restricted diet after bariatric procedures. The average caloric intake ranges from 400-800 kcal/d in the first month[22]. Calorie restriction has a significant impact on hyperglycemia with reduction of blood glucose levels. In fact, in a recent case-control study[23], post-bariatric diet implemented before metabolic surgery resulted in more profound glucose reduction in T2DM patients than in the post-surgical period, indicating the role of calorie restriction in glycemic control after bariatric procedures. Very low calorie diet alone resulted in improvement of insulin sensitivity and β-cell function in obese T2DM cases (comparable to those who had bariatric surgery) in the short-term[24]. Generally, a calorie-restricted diet should be maintained in patients following metabolic surgery on a long-term basis.

Alterations in gut hormones

The acceleration of gastrointestinal transit time after bariatric procedures results in augmented secretion of gut hormones such as glucagon-like peptide-1 (GLP-1), Glucose-dependent insulinotropic peptide (GIP) peptide-YY (PYY) and oxyntomodulin (OXM) that alter energy and glucose metabolism[25]. The anorexient and weight losing properties of GLP-1 is well established in experimental and clinical models. Several studies showed significant elevation of GLP-1 levels during oral glucose challenge and with meals after bariatric procedures such as SG[26], RYGB[27] and BPD[28]. Elevated GLP-1 levels following metabolic surgery was also shown to reverse the obesity-induced endothelial dysfunction conferring cardiovascular protection in the obese[29].

Increased PYY levels following bariatric procedures result in weight loss in obese subjects. PYY administration resulted in a 30% reduction in the calorific value of a meal consumed 2 h after PYY infusion and a 33% reduction in food consumption over 24 h period in human beings[30]. Similarly, OXM administration has been shown to reduce appetite, amount of food ingested and body weight[31]. Ghrelin (a gut-derived peptide hormone that stimulates hunger) level was found to be low after RYGB, whereas the level was high in diet-induced weight loss, indicating the impact of suppression of hunger signals in subjects following bariatric surgery[32]. Hypergastrinemia following SG has been recently reported in rat models of T2DM, although its impact on metabolic pathways and body weight changes have been unclear[33]. The alteration in these gastrointestinal hormonal factors together contributes to significant improvement in T2DM and the body weight of the individual.

Pancreatic β-cell function

Improvement in insulin sensitivity and pancreatic β-cell function are important factors that contribute to improvement/remission of T2DM in obese subjects. Increase in secretion of incretin hormones (GLP-1 and GIP) and proliferation of the β-cell mass have been demonstrated following bariatric procedures in human beings and experimental animals[34]. Although these factors clearly contribute to T2DM control, there may be other mechanisms which are not yet clear.

Hepatic and peripheral insulin sensitivity

Significant improvement of hepatic insulin sensitivity is observed within few days of bariatric procedure, much earlier and before significant weight loss occurs. Reduction of energy intake from the post-bariatric diet may contribute significantly to the improvement in hepatic insulin sensitivity. Although peripheral insulin sensitivity is not altered in the immediate post-operative period, delayed improvement is observed in patients[25,35]. Reduced hepatic fat content and body weight loss account for the sustained improvements in hepatic and peripheral insulin sensitivity during long-term follow up of patients who had metabolic surgery[25].

Role of bile acids

Bariatric procedures were shown to increase the plasma levels of bile acids that improved glucose and lipid metabolism[25,36]. However, the exact mechanisms by which bile acids improve glycemic control and body weight remain elusive.

Gut microbiata

Major changes in the gut microbiota have been demonstrated following bariatric procedures in animal models and human beings[37]. Increase in numbers of some of these intestinal microbial flora, and the related changes in the gut biochemical environment, may affect glucose and lipid metabolism that contribute to weight loss and diabetes improvement[25,37]. More research is necessary on the role of gut flora in glucose and fat metabolism following bariatric procedures.

Body weight loss and diabetes remission

The major mechanism by which improvement and/or remission of T2DM occurs in obese subjects following metabolic surgery is the significant weight loss after the procedure. Analysis of participants in the Look AHEAD (Action For Health in Diabetes) study clearly showed a progressive increase in odds ratios for HbA1c reduction with higher proportions of weight loss[38]. The odds ratios for % weight reduction (in parenthesis) were: 1.80 (≥ 2 to < 5), 3.52 (≥ 5 to < 10), 5.44 (≥ 10 to < 15) and 10.02 (≥ 15%) respectively for HbA1c reduction of 0.05% in the study subjects. Substantial loss of body weight post-bariatric surgery therefore would explain the remarkable improvements in glycemic control and even remission of T2DM in the majority of patients.

Overall, a multitude of physiological, behavioural and anatomical alterations following the bariatric procedure result in significant improvements in metabolic and glycemic parameters that may even result in potential cure of T2DM in a good number of patients after the metabolic surgery.

COST BENEFITS AND OTHER HEALTH-RELATED OUTCOMES

Data from the National Bariatric Surgery Registry (NBSR) of the United Kingdom that included 18283 cases from 2010 to 2013 clearly showed compelling evidence of the cost effectiveness of bariatric surgery as a treatment option for severely obese T2DM patients[39]. NBSR data showed that 61% of patients with obstructive sleep apnoea could come off their treatment after surgery 65% of patients with T2DM could stop their diabetic medications. A recent systematic review and meta-analysis revealed important cardioprotective effects of metabolic surgery in terms of regression of left ventricular hypertrophy, improvement of diastolic function and reduction of left atrial size[40]. Improvement of hypertension, hypercholesterolemia, gastro-esophageal reflux disease, and arthritis are some of the other reported major beneficial effects of bariatric surgery[41].

IMMEDIATE AND LONG-TERM COMPLICATIONS

The main complications in the immediate post-operative period are pulmonary complications, vomiting, wound infections, bleeding and anastomotic leak[16,17]. In a recent systematic review and meta-analysis the peri-operative and post-operative mortality rates were 0.08% and 0.31% respectively in RCTs and 0.22% and 0.35% respectively in OBS[4]. The overall complication rates were 17% in RCTs and 10% in OBS, and the reoperation rates were 7% and 6% respectively.

The most common long-term complications were iron deficiency anaemia in up to 15% of cases and re-operations in up to 8%[14,16]. Psychological issues are emerging as an important complication on follow up of the cases, and alcohol overconsumption and substance misuse are increasingly being reported in patients on long-term follow up[16,42]. For unknown reasons, the suicidal rates were found to be higher in patients who underwent bariatric surgery[16,20]. Nutritional deficiencies including deficiencies of calcium, vitamin D, iron, zinc, and copper, are common after bariatric surgery[16,43]. Periodic checking for deficiencies and nutritional supplements are indicated in patients.

Massive weight loss after the surgery may result in abnormal body contour because of extensive skin folds that may affect the psychological well being of many patients. Body contouring surgery improves this problem and may help improvement of physical and mental well being in these patients although financial cost may become an issue in many healthcare systems[44]. Post-prandial hypoglycaemia is a common problem in many patients after metabolic surgery. Rapid transit of contents from stomach with smaller capacity could be a reason in many cases that can be treated with small frequent meals and complex carbohydrates. However, severe hypoglycaemic episodes caused by hyperinsulinemia from pancreatic islet cell hyperplasia (nesidioblastosis) can sometimes be crippling necessitating pancreas resection, reversal of gastric bypass and restriction of gastric pouch in extreme cases[45].

Diabetic microvascular complications such as retinopathy, neuropathy and nephropathy can sometimes get worse if there is rapid (abrupt) improvement of longstanding severe dysglycemia in patients with poorly controlled diabetes. A similar situation could be expected following metabolic surgery with acute improvement in glycaemic control. There is some evidence of worsening of pre-existing diabetic retinopathy in a proportion of cases following bariatric procedures, although improvement of the disease is also noted in some others[46,47]. Therefore, counselling about this potential complication before surgery and close monitoring after the procedure are advisable. Though the data is insufficient, there is some evidence for improvement of diabetic neuropathy[48] and nephropathy[49] after bariatric surgery. There are no reports of worsening of these conditions after improvement of T2DM following bariatric procedures.

Pregnancies after bariatric surgery were found to be associated with significantly lower risk of gestational diabetes [odds ratio (OR): 0.25; 95%CI: 0.13–0.47], large-for-gestational-age infants (OR: 0.33; 95%CI: 0.24-0.44) and shorter gestation (mean difference: –4.5 d; 95%CI: –2.9 to –6 d; P < 0.001)[50]. However, there were significantly higher risk of small-for gestational-age infants (OR: 2.20; 95%CI: 1.64-2.95; P < 0.001). The risk of stillbirth or neonatal death post-bariatric pregnancies appeared to be higher [1.7% vs 0.7% (OR: 2.39; 95%CI: 0.98-5.85; P = 0.06)] although this risk did not reach statistical significance.

APPROPRIATE PATIENT CATEGORY FOR METABOLIC SURGERY

There is no clear and uniform consensus from different international bodies about the minimum BMI cut off for consideration of the bariatric procedure in obese individuals. The National Institute for Health and Clinical Care Excellence (NICE) of the United Kingdom recently recommended bariatric surgery for people with a BMI of > 40 kg/m2 and > 35 kg/m2 in the presence of co-morbidities such as T2DM or hypertension[51]. For people of Asian family origin a lower BMI threshold should be considered. NICE also recommends expedited assessment for Bariatric surgery to people with BMI of 30-34.9 kg/m2 who have recent onset T2DM. This is based on the evidence that earlier intervention can improve the chances of remission following bariatric surgery[39].

The Canadian Diabetes Association Clinical Practice Guidelines (2013) recommend bariatric surgery for people with class III obesity (BMI ≥ 40.0 kg/m2) or class II obesity (BMI = 35.0 to 39.9 kg/m2) in the presence of co-morbidities, with an inability to maintain weight loss following adequate trial of health behaviour intervention[52].

The American Association of Clinical Endocrinologists, the Obesity Society and the American Society for Metabolic and Bariatric Surgery (2013) recommend metabolic surgery in obese individuals with a BMI of ≥ 40 kg/m2 without coexisting medical problems and surgical risk[53]. For patients with BMI ≥ 35 kg/m2, surgery may be offered if one or more severe obesity-related co-morbidities exist including T2D, hypertension, hyperlipidemia, obstructive sleep apnea (OSA), obesity-hypoventilation syndrome (OHS), Pickwickian syndrome (a combination of OSA and OHS), nonalcoholic fatty liver disease or nonalcoholic steatohepatitis, pseudotumor cerebri, gastroesophageal reflux disease, asthma, venous stasis disease, severe urinary incontinence, debilitating arthritis, or considerably impaired quality of life. Patients with BMI of 30–34.9 kg/m2 and T2DM or metabolic syndrome may also be offered a bariatric procedure, although evidence for this recommendation is inadequate with the unavailability of long-term data[53].

With robust clinical and epidemiological data emerging from all continents of the world, a global consensus on the appropriate patient categories that get definite benefits from metabolic surgery is expected to emerge in the near future.

AREAS OF UNCERTAINTY

Although there is accumulated experience from different regions of the world on the excellent outcomes of bariatric procedures, there is not enough data from resource poor nations of Asia, Arabian Peninsula, Africa and South America to generalise the recommendations of metabolic surgery, even though obesity epidemic is becoming a public health issue in these regions. Moreover, the BMI cut off for obesity in Asians is different from that of the western populations. For example BMI of ≥ 25 kg/m2 is considered as obesity in India[54] and ≥ 27 kg/m2 in Taiwan[55]. Diabesity (diabetes caused by overweight or obesity) is different for populations of Asian and Afro-Caribbean ethnic background owing to the difference in abdominal adiposity in these groups compared to other races, making generalisation of BMI cut offs metabolic surgery inappropriate.

For a common condition like diabetes there are only a handful of RCT’s of short duration comparing bariatric surgery to medical therapy which ranged from standard care to intensive medical intervention. There are a few prospective studies available on long term outcomes of bariatric surgery. However, T2DM being a lifelong multisystem disease with almost all organs of the body involved, more data based on lifelong follow up of cases is necessary to understand the true impact of bariatric procedures. This requires maintenance of nationwide bariatric registries globally along the lines of NBSR in the UK which can provide valuable information.

Though there are some studies on the impact of bariatric surgery on the psychosocial, nutritional and mineral metabolic status of patients, long-term data on these areas are still inadequate. Similarly the optimal management of post-bariatric nesidioblastosis that emerged as a challenging clinical problem is not yet clear.

Different multicentre on-going prospective clinical trials would be expected to answer these unresolved questions.

CONCLUSION

Metabolic surgery is emerging as a major paradigm shift in the 21st Century management of T2DM, and has revolutionised the care of diabesity. Massive weight loss with remission of T2DM in a significant proportion of cases along with improvement of most other obesity-related ailments makes the treatment a very attractive option for clinicians and patients. A recent analysis of the NBSR data clearly showed its cost effectiveness. Appropriate patient selection and long-term follow up of cases are necessary to optimise the outcomes and reduce the complications.

Footnotes

P- Reviewer: Gómez-Sáez J, Takebayashi K S- Editor: Ji FF L- Editor: A E- Editor: Jiao XK

References
1.  World Health Organization. Obesity and overweight. 2015. [assessed 2015 March 8].  Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html.  [PubMed]  [DOI]
2.  Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311:806-814.  [PubMed]  [DOI]
3.  International Diabetes Federation. IDF Diabetes Atlas Update 2014. [assessed 2015 March 8].  Available from: http://www.idf.org/diabetesatlas/5e/Update2014.  [PubMed]  [DOI]
4.  Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149:275-287.  [PubMed]  [DOI]
5.  Skroubis G, Kouri N, Mead N, Kalfarentzos F. Long-term results of a prospective comparison of Roux-en-Y gastric bypass versus a variant of biliopancreatic diversion in a non-superobese population (BMI 35-50 kg/m(2)). Obes Surg. 2014;24:197-204.  [PubMed]  [DOI]
6.  Maleckas A, Venclauskas L, Wallenius V, Lönroth H, Fändriks L. Surgery in the treatment of type 2 diabetes mellitus. Scand J Surg. 2015;104:40-47.  [PubMed]  [DOI]
7.  Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577-1585.  [PubMed]  [DOI]
8.  Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316-323.  [PubMed]  [DOI]
9.  Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567-1576.  [PubMed]  [DOI]
10.  Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ, Leslie DB, Chong K, Jeffery RW. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309:2240-2249.  [PubMed]  [DOI]
11.  Liang Z, Wu Q, Chen B, Yu P, Zhao H, Ouyang X. Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Pract. 2013;101:50-56.  [PubMed]  [DOI]
12.  Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg. 2014;24:437-455.  [PubMed]  [DOI]
13.  Parikh M, Issa R, Vieira D, McMacken M, Saunders JK, Ude-Welcome A, Schubart U, Ogedegbe G, Pachter HL. Role of bariatric surgery as treatment for type 2 diabetes in patients who do not meet current NIH criteria: a systematic review and meta-analysis. J Am Coll Surg. 2013;217:527-532.  [PubMed]  [DOI]
14.  Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, Bucher HC, Nordmann AJ. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347:f5934.  [PubMed]  [DOI]
15.  Li JF, Lai DD, Ni B, Sun KX. Comparison of laparoscopic Roux-en-Y gastric bypass with laparoscopic sleeve gastrectomy for morbid obesity or type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Can J Surg. 2013;56:E158-E164.  [PubMed]  [DOI]
16.  Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults. BMJ. 2014;349:g3961.  [PubMed]  [DOI]
17.  Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219-234.  [PubMed]  [DOI]
18.  Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-2693.  [PubMed]  [DOI]
19.  Carlsson LM, Peltonen M, Ahlin S, Anveden Å, Bouchard C, Carlsson B, Jacobson P, Lönroth H, Maglio C, Näslund I. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367:695-704.  [PubMed]  [DOI]
20.  Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, Lamonte MJ, Stroup AM, Hunt SC. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753-761.  [PubMed]  [DOI]
21.  Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, Horlick M, Kalarchian MA, King WC, Mitchell JE. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA. 2013;310:2416-2425.  [PubMed]  [DOI]
22.  Elrazek AE, Elbanna AE, Bilasy SE. Medical management of patients after bariatric surgery: Principles and guidelines. World J Gastrointest Surg. 2014;6:220-228.  [PubMed]  [DOI]
23.  Lingvay I, Guth E, Islam A, Livingston E. Rapid improvement in diabetes after gastric bypass surgery: is it the diet or surgery? Diabetes Care. 2013;36:2741-2747.  [PubMed]  [DOI]
24.  Jackness C, Karmally W, Febres G, Conwell IM, Ahmed L, Bessler M, McMahon DJ, Korner J. Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β-cell Function in type 2 diabetic patients. Diabetes. 2013;62:3027-3032.  [PubMed]  [DOI]
25.  Cho YM. A gut feeling to cure diabetes: potential mechanisms of diabetes remission after bariatric surgery. Diabetes Metab J. 2014;38:406-415.  [PubMed]  [DOI]
26.  Tsoli M, Chronaiou A, Kehagias I, Kalfarentzos F, Alexandrides TK. Hormone changes and diabetes resolution after biliopancreatic diversion and laparoscopic sleeve gastrectomy: a comparative prospective study. Surg Obes Relat Dis. 2013;9:667-677.  [PubMed]  [DOI]
27.  Bose M, Machineni S, Oliván B, Teixeira J, McGinty JJ, Bawa B, Koshy N, Colarusso A, Laferrère B. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring). 2010;18:1085-1091.  [PubMed]  [DOI]
28.  Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG. Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. Obes Surg. 2007;17:1193-1198.  [PubMed]  [DOI]
29.  Osto E, Doytcheva P, Corteville C, Bueter M, Dörig C, Stivala S, Buhmann H, Colin S, Rohrer L, Hasballa R. Rapid and body weight-independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass: role of glucagon-like peptide-1. Circulation. 2015;131:871-881.  [PubMed]  [DOI]
30.  Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418:650-654.  [PubMed]  [DOI]
31.  Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost GS, Meeran K, Ghatei MA. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes. 2005;54:2390-2395.  [PubMed]  [DOI]
32.  Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623-1630.  [PubMed]  [DOI]
33.  Grong E, Arbo IB, Thu OK, Kuhry E, Kulseng B, Mårvik R. The effect of duodenojejunostomy and sleeve gastrectomy on type 2 diabetes mellitus and gastrin secretion in Goto-Kakizaki rats. Surg Endosc. 2015;29:723-733.  [PubMed]  [DOI]
34.  Rubino F, Amiel SA. Is the gut the “sweet spot” for the treatment of diabetes? Diabetes. 2014;63:2225-2228.  [PubMed]  [DOI]
35.  Bojsen-Møller KN, Dirksen C, Jørgensen NB, Jacobsen SH, Serup AK, Albers PH, Hansen DL, Worm D, Naver L, Kristiansen VB. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes. 2014;63:1725-1737.  [PubMed]  [DOI]
36.  Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E, Mun EC, Pihlajamaki J. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring). 2009;17:1671-1677.  [PubMed]  [DOI]
37.  Liou AP, Paziuk M, Luevano JM, Machineni S, Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013;5:178ra41.  [PubMed]  [DOI]
38.  Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481-1486.  [PubMed]  [DOI]
39.  Wise J. Audit shows that bariatric surgery is cost effective. BMJ. 2014;349:g6735.  [PubMed]  [DOI]
40.  Cuspidi C, Rescaldani M, Tadic M, Sala C, Grassi G. Effects of bariatric surgery on cardiac structure and function: a systematic review and meta-analysis. Am J Hypertens. 2014;27:146-156.  [PubMed]  [DOI]
41.  Li JF, Lai DD, Lin ZH, Jiang TY, Zhang AM, Dai JF. Comparison of the long-term results of Roux-en-Y gastric bypass and sleeve gastrectomy for morbid obesity: a systematic review and meta-analysis of randomized and nonrandomized trials. Surg Laparosc Endosc Percutan Tech. 2014;24:1-11.  [PubMed]  [DOI]
42.  King WC, Chen JY, Mitchell JE, Kalarchian MA, Steffen KJ, Engel SG, Courcoulas AP, Pories WJ, Yanovski SZ. Prevalence of alcohol use disorders before and after bariatric surgery. JAMA. 2012;307:2516-2525.  [PubMed]  [DOI]
43.  Gletsu-Miller N, Wright BN. Mineral malnutrition following bariatric surgery. Adv Nutr. 2013;4:506-517.  [PubMed]  [DOI]
44.  Azin A, Zhou C, Jackson T, Cassin S, Sockalingam S, Hawa R. Body contouring surgery after bariatric surgery: a study of cost as a barrier and impact on psychological well-being. Plast Reconstr Surg. 2014;133:776e-782e.  [PubMed]  [DOI]
45.  Mala T. Postprandial hyperinsulinemic hypoglycemia after gastric bypass surgical treatment. Surg Obes Relat Dis. 2014;10:1220-1225.  [PubMed]  [DOI]
46.  Cheung D, Switzer NJ, Ehmann D, Rudnisky C, Shi X, Karmali S. The Impact of Bariatric Surgery on Diabetic Retinopathy: A Systematic Review and Meta-Analysis. Obes Surg. 2014;Epub ahead of print.  [PubMed]  [DOI]
47.  Murphy R, Jiang Y, Booth M, Babor R, MacCormick A, Hammodat H, Beban G, Barnes RM, Vincent AL. Progression of diabetic retinopathy after bariatric surgery. Diabet Med. 2015;Epub ahead of print.  [PubMed]  [DOI]
48.  Müller-Stich BP, Fischer L, Kenngott HG, Gondan M, Senft J, Clemens G, Nickel F, Fleming T, Nawroth PP, Büchler MW. Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization--results of a prospective cohort study (DiaSurg 1 study). Ann Surg. 2013;258:760-765; discussion 765-766;.  [PubMed]  [DOI]
49.  Brethauer SA, Aminian A, Romero-Talamás H, Batayyah E, Mackey J, Kennedy L, Kashyap SR, Kirwan JP, Rogula T, Kroh M. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258:628-636; discussion 636-637.  [PubMed]  [DOI]
50.  Johansson K, Cnattingius S, Näslund I, Roos N, Trolle Lagerros Y, Granath F, Stephansson O, Neovius M. Outcomes of pregnancy after bariatric surgery. N Engl J Med. 2015;372:814-824.  [PubMed]  [DOI]
51.  Stegenga H, Haines A, Jones K, Wilding J. Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance. BMJ. 2014;349:g6608.  [PubMed]  [DOI]
52.  Wharton S, Sharma AM, Lau DC. Weight management in diabetes. Can J Diabetes. 2013;37 Suppl 1:S82-S86.  [PubMed]  [DOI]
53.  Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, Heinberg LJ, Kushner R, Adams TD, Shikora S. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & amp; Bariatric Surgery. Obesity (Silver Spring). 2013;21 Suppl 1:S1-27.  [PubMed]  [DOI]
54.  Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, Joshi SR, Sadikot S, Gupta R, Gulati S. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009;57:163-170.  [PubMed]  [DOI]
55.  Pan WH, Lee MS, Chuang SY, Lin YC, Fu ML. Obesity pandemic, correlated factors and guidelines to define, screen and manage obesity in Taiwan. Obes Rev. 2008;9 Suppl 1:22-31.  [PubMed]  [DOI]